Fibrodysplasia Ossificans Progressiva (FOP) Treatment Market Report 2025

The fibrodysplasia ossificans progressiva (FOP) treatment market size has grown strongly in recent years. It will grow from $0.46 billion in 2024 to $0.5 billion in 2025 at a compound annual growth rate (CAGR) of 9.6%. The growth during the historic period can be attributed to increased awareness of rare diseases, a rising prevalence of FOP cases, higher investments in orphan drug development, collaborations between biotech companies and research institutions, and supportive regulatory frameworks for treatments of rare diseases.

The fibrodysplasia ossificans progressiva (FOP) treatment market size is expected to see strong growth in the next few years. It will grow to $0.71 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth during the forecast period can be attributed to the rise in clinical trials for innovative treatment options, increased investments in rare disease research, growing patient awareness initiatives, enhanced diagnostic capabilities, supportive regulatory frameworks for orphan drugs, and the expansion of healthcare infrastructure in emerging markets. Key trends expected in this period include advancements in gene therapy, CRISPR-based genome editing, the adoption of anti-inflammatory biologics, small molecule inhibitors targeting ACVR1 mutations, personalized medicine approaches, advanced imaging techniques, and patient-centered rehabilitation programs.

The growing adoption of gene therapy is expected to drive the expansion of the fibrodysplasia ossificans progressiva (FOP) treatment market. Gene therapy involves modifying or replacing genes within a person’s cells to treat or prevent diseases. This trend is being fueled by advancements in genetic research, better treatment outcomes for conditions that were once untreatable, and increasing regulatory support for innovative therapies. In the case of FOP, gene therapy focuses on correcting mutations in the ACVR1 gene to prevent abnormal bone growth. For example, in April 2024, the American Society of Gene & Cell Therapy reported a 10% increase in the number of phase III gene therapy clinical trials in the fourth quarter, marking the first quarterly rise since the third quarter of 2022. As a result, the growing adoption of gene therapy is contributing to the growth of the FOP treatment market.

Key companies in the FOP treatment market are working on developing advanced drugs such as retinoid-induced capsules to meet the medical needs of patients by targeting the genetic mutations responsible for the condition, thereby improving treatment outcomes and overall quality of life. Retinoids, which are vitamin A derivatives, are used to regulate cell growth and support immune functions, particularly in skin and certain cancer treatments. For instance, in August 2023, Ipsen, a pharmaceutical company based in France, received approval from the US Food and Drug Administration (FDA) for its sohonos capsules. This retinoid-based medication is designed to treat FOP by reducing new abnormal bone growth (heterotopic ossification) and offers an important treatment option for both adult and pediatric patients, helping to improve mobility and quality of life.

In March 2024, the International Fibrodysplasia Ossificans Progressiva Association (IFOPA), a US-based non-profit, formed a partnership with Wazoku Crowd to accelerate research, support families impacted by FOP, and further the search for a cure. Wazoku Crowd, a UK-based innovation and crowdsourcing company, provides a platform that allows organizations to gather ideas, solutions, and innovations from a wide range of contributors.

Major players in the fibrodysplasia ossificans progressiva (FOP) treatment market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Bristol Myers Squibb Company, Novartis AG, AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, UCB S.A., Incyte Corporation, Ipsen Pharma, Alnylam Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Blueprint Medicines Corporation, BioCryst Pharmaceuticals Inc., and Ashibio.

North America was the largest region in the fibrodysplasia ossificans progressiva (FOP) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in fibrodysplasia ossificans progressiva (FOP) treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the fibrodysplasia ossificans progressiva (FOP) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Fibrodysplasia ossificans progressiva (FOP) treatment involves medical interventions designed to manage this rare genetic disorder, in which soft tissues gradually turn into bone. Treatment approaches include medications, surgery, and gene therapy to help control symptoms and slow disease progression. The primary goals are to reduce inflammation, prevent further bone formation, and enhance the quality of life for those affected.

The main drug classes used in FOP treatment include corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), bisphosphonates, and others. Corticosteroids are particularly effective in reducing inflammation and regulating immune responses in various conditions. Treatment options range from medication and surgery to occupational therapy, administered through oral, topical, or parenteral routes. These treatments are provided in hospitals, research institutes, and specialty clinics.

The fibrodysplasia ossificans progressiva (FOP) treatment market research report is one of a series of new reports that provides fibrodysplasia ossificans progressiva (FOP) treatment market statistics, including the fibrodysplasia ossificans progressiva (FOP) treatment industry's global market size, regional shares, competitors with a fibrodysplasia ossificans progressiva (FOP) treatment market share, detailed fibrodysplasia ossificans progressiva (FOP) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the fibrodysplasia ossificans progressiva (FOP) treatment industry. This fibrodysplasia ossificans progressiva (FOP) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The fibrodysplasia ossificans progressiva (FOP) treatment market consists of revenues earned by entities by providing services such as supportive therapies, physical therapy, and genetic counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The fibrodysplasia ossificans progressiva (FOP) treatment market also includes sales of bone morphogenetic protein (BMP) inhibitors, anti-inflammatory drugs, pain relievers, muscle relaxants, pain relievers, and muscle relaxants care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.